Outpatient Psychotherapy denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for outpatient psychotherapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Outpatient Psychotherapy as Not FDA-Approved

This denial reason, when applied to outpatient psychotherapy, reflects a misapplication of the FDA-approval framework. The FDA regulates drugs, devices, and biologics — not psychotherapy services, which are professional clinical services delivered by licensed practitioners and are not subject to FDA premarket approval. When BCBS issues a "not FDA-approved" denial for a psychotherapy service, it is almost always either a coding error, a mismatch between the denial boilerplate and the actual basis for the decision, or a misclassification of a specific therapeutic protocol as an unapproved "device" or "treatment."

This denial is strong grounds for appeal precisely because the stated rationale is legally and factually inapplicable to professional psychotherapy services. The appeal should directly challenge the premise — outpatient psychotherapy delivered by a licensed mental health professional does not require FDA approval, and BCBS cannot legitimately deny covered behavioral health benefits on that basis.

## Federal Appeal Framework

• Internal appeal: File within the deadline in the denial letter (often 180 days). BCBS must respond within 30 days (pre-service) or 60 days (post-service).
• External review (ACA §2719 / ERISA §503): After exhausting internal remedies, request independent external review within approximately 4 months (120 days) of the final denial. If a "not FDA-approved" denial is being used as a proxy for an experimental/investigational determination, federal law specifically provides external review rights for that category as well.

## Documentation to Gather

1. Provider licensure and credentials — documentation that the treating clinician holds a current state license to practice the type of therapy delivered (e.g., LCSW, PhD, PsyD, LPC, LMFT, MD/DO). 2. Service description — a clear description of the psychotherapy modality delivered, including the procedure code billed, to demonstrate it is a professional service not a drug or device. 3. Plan documents — the Summary Plan Description or Evidence of Coverage establishing that outpatient mental health services by licensed providers are a covered benefit. 4. Treating clinician's letter — a letter confirming the nature of the service delivered and noting that FDA approval is not applicable to licensed professional psychotherapy services. 5. BCBS policy request — a written request for the specific policy basis for the denial, including the text of the coverage criteria invoked, so the appeal can address the actual underlying concern.

## Criteria-Mapping Structure

Because the stated denial reason is legally inapplicable, the appeal letter's primary argument is categorical: identify that the service is professional psychotherapy, cite the provider's license, note that the FDA does not regulate licensed clinical services of this type, and demand that BCBS identify any remaining legitimate coverage concern. Then address that concern directly with the clinical record. If BCBS's real objection is that a specific protocol lacks evidence, address it using the medical-necessity and experimental frameworks above.